Arcus Biosciences Inc (RCUS) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.

Total Cash From Operating Activities Chart for Arcus Biosciences Inc

Arcus Biosciences Inc (RCUS) operating cash flow for FY2025 was USD -482.0M. Arcus Biosciences Inc's operating cash flow moved from USD -12.9M in 2016 to USD -482.0M in 2025 over 9 years.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$2.33B
Implied Share Price
$18.54
Enterprise Value
$2.55B
Revenue (TTM)
$117.00M
EBITDA
-$476.00M
Profit Margin
0.00%
Trailing P/E
—
Forward P/E
0.00
Price/Book (MRQ)
6.76
Price/Sales (TTM)
19.93
EV/EBITDA
3.96
EV/Revenue
21.80
Dividend Yield
—
Book Value
$3.65
Free Cash Flow (FY2025)
-$484.00M
Free Cash Flow Yield
-20.76%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.